DuChemBio

176750 · KOSDAQ · ₩176750 · 듀켐바이오

₩6,400▼ ₩760 (10.61%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩4,081

vs the current price (₩6,400)

Enterprise value
₩115B
Equity value
₩116B
WACC
7.3%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 36% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩6,400, the model needs an operating margin of 27.3% every year (it uses 17.7%).
  • Or revenue growth +11.2 points a year higher than assumed in each of the 5 years.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩2,671
−58.3%
Base
₩4,081
−36.2%
Bull
₩6,409
+0.1%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (17.7%).

Revenue growth

  • 8.3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.

  • 7%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.

  • 5.7%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.

  • 4.3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8.3% a year, annual reports), fading to 3% by year 5.

Business

  • 17.7%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 3%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 3.8%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).

  • 8.9%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.01%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-30.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.07, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.51%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩42B
Net debt (borrowings and leases − cash and deposits)
₩1.7B
+ Stakes and investments
₩2.7B
Associates, long-term financial assets and deposits (book value)
Shares
28,488,720
Share price
₩6,400
Market cap
₩182B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩36B₩39B₩45B₩48B₩51B₩53B₩55B
Growth—8.3%8.3%7.0%5.7%4.3%3.0%
EBIT₩5.1B₩7.4B₩8B₩8.5B₩9B₩9.4B₩9.7B
EBIT margin14.3%19.3%17.7%17.7%17.7%17.7%17.7%
After-tax EBIT₩3.7B₩5.4B₩5.8B₩6.2B₩6.5B₩6.8B₩7B
+ Depreciation——₩1.3B₩1.4B₩1.5B₩1.6B₩1.6B
− Capital spending₩1.9B₩878M₩1.7B₩1.8B₩1.9B₩2B₩2.1B
− Working capital—−₩2.7B₩307M₩280M₩244M₩195M₩142M
Free cash flow——₩5.1B₩5.5B₩5.9B₩6.2B₩6.4B
Discount factor——0.9320.8690.8100.7550.704
Present value——₩4.8B₩4.8B₩4.8B₩4.7B₩4.5B

Terminal value ₩130B, worth ₩92B today: 80% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.3%₩4,250₩4,607₩5,048₩5,606₩6,334
6.8%₩3,875₩4,164₩4,514₩4,945₩5,490
7.3%₩3,560₩3,798₩4,081₩4,423₩4,844
7.8%₩3,292₩3,491₩3,723₩4,000₩4,334
8.3%₩3,061₩3,228₩3,422₩3,650₩3,920

Now (TTM)

Market cap
₩182B
Enterprise value
₩169B
P/E
26.7×
P/B
3.5×
P/S
4.4×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

20252024
Price₩9,520₩8,150
Market cap₩271B₩232B
P/E41.9×29.0×
P/B5.5×5.4×
P/S7.0×6.5×
EV/EBITDA——
Dividend yield0.0%—

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
DuChemBio26.7×3.5×4.4×—0.0%
Samsung Biologics31.9×7.6×13.9×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen79.4×28.6×60.3×—0.1%
SK biopharmaceuticals15.2×6.0×7.1×—0.0%
Yuhan23.2×2.3×2.4×30.2×0.8%
HLB—15.4×54.3×—0.0%
Similar companies (median)27.9×6.8×11.4×30.2×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: DuChemBio / 듀켐바이오 / 176750 / KRX:176750

Source: KRX statistical information